Pharmacokinetics of cilazapril during repeated oral dosing in healthy young volunteers.
The pharmacokinetics of cilazapril and its active metabolite cilazaprilat in plasma were investigated in an open study of 13 healthy male volunteers, aged 18 to 43 years. One capsule containing 2.5 mg cilazapril was administered to each volunteer daily for 8 days. Plasma samples were obtained after the first and eighth doses. Concentrations of cilazapril, cilazaprilat and activities of angiotensin converting enzyme (ACE) were measured by radioenzymatic methods. For cilazapril, the values of apparent plasma clearance (about 15 l/h) and volume of distribution (around 28 l) were sufficiently high to suggest that significant pre-systemic hydrolysis to cilazaprilat occurred. There were no significant changes in these values after repeated dosing. There were small, but statistically significant, increases in mean peak concentrations, mean areas under concentration-time curves and mean trough concentrations from the first to the eighth dose. A steady state was achieved after eight doses with an accumulation of 20-30%. The mean effective half-life was approximately 9 h. Despite the accumulation of cilazaprilat in plasma, there were no significant differences in plasma ACE inhibition from the first to the eighth dose.
Williams
P E
PE
Roche Products Ltd, Welwyn Garden City, Herts, UK.
Brown
A N
AN
Rajaguru
S
S
Francis
R J
RJ
Bell
A J
AJ
Dewland
P M
PM
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D017315:Cilazapril / Q000031:analogs & derivatives; D006207:Half-Life; D006801:Humans; D008297:Male; D007703:Peptidyl-Dipeptidase A / Q000097:blood; D011724:Pyridazines / Q000097:blood / Q000493:pharmacokinetics*; D012016:Reference Values
D011724:Pyridazines; D017315:Cilazapril; D007703:Peptidyl-Dipeptidase A; C045980:cilazaprilat